$CMPX News

Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile

Compass Therapeutics Q1 EPS $(0.10), Inline

Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7

Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics shares are trading lower after the company announced that its tovecimig candidate did not meet the overall survival secondary endpoint in a phase 2/3 study.

Compass Therapeutics shares are trading lower after the company announced that its tovecimig candidate did not meet the overall survival secondary endpoint in a phase 2/3 study.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Compass Therapeutics Announces That Tovecimig Did Not Meet The Overall Survival Secondary Endpoint

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Compass Therapeutics To Host Webcast On April 27 To Review Topline Secondary Endpoints From Phase 2/3 COMPANION-002 Clinical Study Assessing Tovecimig In Combination With Paclitaxel In Advanced Biliary Tract Cancer

Guggenheim Reiterates Buy on Compass Therapeutics, Maintains $12 Price Target

Compass Therapeutics Q4 EPS $(0.09) Beats $(0.10) Estimate

Compass Therapeutics: Exciting Clinical Updates Inbound For 2026

Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $30 Price Target

Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care

William Blair Initiates Coverage On Compass Therapeutics with Outperform Rating